Patient and Transplant Characteristics
| . | . | No. of Patients . | (%) . |
|---|---|---|---|
| All patients | 212 | (100) | |
| Age at BMT (yrs) | |||
| Median | 18 | — | — |
| (Range) | (1-42) | — | — |
| Age at last follow-up (yrs)* | |||
| Median | 32 | — | — |
| (Range) | (7-58) | — | — |
| Sex | |||
| Male | 115 | (55) | |
| Female | 95 | (45) | |
| Source of marrow | |||
| Syngeneic | 3 | (1) | |
| Matched sibling | 187 | (88) | |
| Mismatched related | 17 | (8) | |
| Unrelated | 5 | (2) | |
| Etiology of aplastic anemia | |||
| Chemical/drug | 20 | (10) | |
| Chloramphenicol | 3 | (1) | |
| Genetic-151 | 7 | (4) | |
| Hepatitis | 15 | (7) | |
| Idiopathic | 156 | (73) | |
| Pure red cell aplasia | 2 | (1) | |
| PNH-152 | 4 | (2) | |
| Pregnancy | 5 | (1) | |
| Conditioning | |||
| TBI + Cy | 15 | (7) | |
| Cy + ATG | 39 | (18) | |
| Cy | 89 | (44) | |
| Cy + buffy coat infusion | 66 | (31) | |
| None-153 | 1 | (<1) | |
| GVHD prophylaxis | |||
| CSP | 7 | (3) | |
| MTX | 111 | (53) | |
| CSP/MTX | 86 | (41) | |
| CSP/MTX/prednisone | 5 | (2) | |
| None-155 | 3 | (1) | |
| Donor/patient sex | |||
| Male/male | 66 | (30) | |
| Female/female | 56 | (27) | |
| Male/female | 51 | (24) | |
| Female/male | 39 | (19) | |
| Donor age (yrs) | |||
| Median | 20 | — | — |
| (Range) | (1-50) | — | — |
| Acute GVHD | |||
| Grades O-I | 157 | (74) | |
| Grades II-IV | 55 | (26) | |
| Chronic GVHD | |||
| Clinical extensive | 86 | (41) |
| . | . | No. of Patients . | (%) . |
|---|---|---|---|
| All patients | 212 | (100) | |
| Age at BMT (yrs) | |||
| Median | 18 | — | — |
| (Range) | (1-42) | — | — |
| Age at last follow-up (yrs)* | |||
| Median | 32 | — | — |
| (Range) | (7-58) | — | — |
| Sex | |||
| Male | 115 | (55) | |
| Female | 95 | (45) | |
| Source of marrow | |||
| Syngeneic | 3 | (1) | |
| Matched sibling | 187 | (88) | |
| Mismatched related | 17 | (8) | |
| Unrelated | 5 | (2) | |
| Etiology of aplastic anemia | |||
| Chemical/drug | 20 | (10) | |
| Chloramphenicol | 3 | (1) | |
| Genetic-151 | 7 | (4) | |
| Hepatitis | 15 | (7) | |
| Idiopathic | 156 | (73) | |
| Pure red cell aplasia | 2 | (1) | |
| PNH-152 | 4 | (2) | |
| Pregnancy | 5 | (1) | |
| Conditioning | |||
| TBI + Cy | 15 | (7) | |
| Cy + ATG | 39 | (18) | |
| Cy | 89 | (44) | |
| Cy + buffy coat infusion | 66 | (31) | |
| None-153 | 1 | (<1) | |
| GVHD prophylaxis | |||
| CSP | 7 | (3) | |
| MTX | 111 | (53) | |
| CSP/MTX | 86 | (41) | |
| CSP/MTX/prednisone | 5 | (2) | |
| None-155 | 3 | (1) | |
| Donor/patient sex | |||
| Male/male | 66 | (30) | |
| Female/female | 56 | (27) | |
| Male/female | 51 | (24) | |
| Female/male | 39 | (19) | |
| Donor age (yrs) | |||
| Median | 20 | — | — |
| (Range) | (1-50) | — | — |
| Acute GVHD | |||
| Grades O-I | 157 | (74) | |
| Grades II-IV | 55 | (26) | |
| Chronic GVHD | |||
| Clinical extensive | 86 | (41) |
*Surviving patients.
Fanconi anemia and “familial” aplastic anemia.
PNH, paroxysmal nocturnal hemoglobinuria; TBI, total body irradiation; Cy, cyclophosphamide; ATG, antithymocyte globulin; CSP, cyclosporine; MTX, methotrexate; GVHD, graft-versus-host disease.
Patients given syngeneic marrow.
One syngeneic recipient.